ESCRS - PP08.10 - Long-Term Outcomes Of Type 1 Keratoprosthesis In A Tertiary Care Centre

Long-Term Outcomes Of Type 1 Keratoprosthesis In A Tertiary Care Centre

Published 2026 - 44th Congress of the ESCRS

Reference: PP08.10 | Type: Free paper | DOI: 10.82333/95xd-w229

Authors: Dr Soumya Sharma* 1 , Dr Yathish Shivanna 1 , Dr Gairik Kundu 1

1Cornea and Refractive surgeries,Narayana Nethralaya,Bangalore,India

Purpose

To evaluate the long-term visual and anatomical outcomes of type 1 keratoprosthesis implantation and to analyze device retention and postoperative complications over extended follow-up in eyes with severe corneal blindness not amenable to conventional keratoplasty.

Setting

Retrospective observational study conducted at a tertiary eye care referral center with dedicated cornea and anterior segment services.

Methods

This retrospective study included 23 eyes from 20 patients who underwent type 1 keratoprosthesis implantation with a minimum follow-up of 5 years. Indications included multiple failed corneal grafts, chemical injury, recurrent viral keratitis, blast injury, and ocular cicatricial pemphigoid. Outcome measures assessed were visual acuity in logMAR units, device retention, and incidence of postoperative complications.

Results

Twenty-three eyes from 20 patients, with a mean age of 46.65 years and a mean follow-up of 8.1 years, were analyzed. Seventy percent were male. Mean preoperative visual acuity was logMAR 2.58. Immediate postoperative mean visual acuity improved to logMAR 1.07, and long-term mean visual acuity was logMAR 1.89. Common complications included infectious keratitis, endophthalmitis, retroprosthetic membrane formation, and carrier graft melts.

Conclusions

Type 1 keratoprosthesis provides significant short-term visual improvement in eyes with complex corneal pathology; however, long-term visual outcomes may decline due to sight-threatening complications. Careful long-term monitoring is essential to optimize device retention and manage postoperative complications, thereby improving overall prosthesis survival and patient outcomes.